Clinical trial accruals at OneOncology increase in the face of COVID-19

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Enrolling patients in clinical trials at OneOncology partner practices has slightly increased in March and April, as the COVID-19 pandemic hit its communities hardest.

OneOncology, a national partnership of independent, community oncology practices, includes five large community oncology practices representing over 400 physicians practicing at more than 160 sites of care in the United States.

“Elective medical procedures have stopped, but caring for cancer patients isn’t elective,” Jeff Patton, OneOncology’s acting CEO and president of Physician Services, said in a statement. “Not only do community oncology centers remain open, providing patients life-saving treatments, we also continue to provide clinical trials at a steady to increased rate. Our centers are continuing to fulfill our collective mission.”

When the Centers for Medicare and Medicaid temporarily loosened its regulations to allow providers to be reimbursed for telehealth visits, the agency allowed researchers to keep some clinical trials open by evaluating and enrolling out-of-state patients.

“By loosening the regulations at both the federal and state levels, we were able to evaluate patients for eligibility in clinical trials that we otherwise couldn’t because of state licensing requirements,” Natalie Dickson, chief medical officer at Tennessee Oncology and chair of OneCouncil, the partnership’s all-physician committee, said in a statement.

Table of Contents

YOU MAY BE INTERESTED IN

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges.  Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login